FDA Warns About Risks Linked to Compounded GLP-1 Drugs: What Patients Need to Know

FDA raises concerns about compounded GLP-1 products

The U.S. Food and Drug Administration (FDA) is warning patients and healthcare professionals about safety risks linked to compounded versions of GLP-1 medications, including semaglutide and tirzepatide. These drugs are widely used to treat type 2 diabetes and, in some cases, for chronic weight management.

In recent safety communications, the FDA reported dosing errors, use of different ingredient forms, contamination concerns, and adverse events associated with some compounded products. The agency emphasized that compounded GLP-1 drugs are not FDA-approved and do not go through the same review for safety, effectiveness, or manufacturing quality as brand-name products.

For patients, the practical takeaway is this: compounded GLP-1 medications can be legal in certain situations, especially during official drug shortages, but they may not be equivalent to FDA-approved products—and they carry specific risks that patients should understand.

Why demand for GLP-1 drugs surged

GLP-1 receptor agonists help lower blood sugar and, in some formulations, support weight loss. According to the CDC, more than 37 million Americans have diabetes, and millions more are living with obesity. High demand for these medications—combined with supply constraints—has led to ongoing shortages in recent years.

Mainstream reporting, including coverage by Reuters, has documented how shortages, high out-of-pocket costs, insurance coverage gaps, and rapid growth in telehealth prescribing contributed to increased use of compounded versions. Some patients turned to compounding pharmacies when brand-name products were unavailable or unaffordable.

What “compounded” means—and how it differs from FDA-approved drugs

Compounding is the practice of preparing customized medications for individual patients, often when a commercially available drug does not meet a specific medical need. Under federal law, licensed pharmacies and certain FDA-registered outsourcing facilities may compound drugs in limited circumstances.

However, compounded drugs:

Are not FDA-approved.
Are not reviewed by the FDA for safety, effectiveness, or quality before they are sold.
May differ in strength, ingredients, or sterility from brand-name products.

During an official FDA-declared drug shortage, compounding of a copy of an approved drug may be permitted under certain conditions. The FDA has also exercised “enforcement discretion” at times—meaning it may temporarily allow certain practices while shortages persist. These policies can evolve as supply conditions change.

What the FDA specifically warned about

In its recent communication on compounded GLP-1 products, the FDA highlighted several areas of concern:

Dosing errors

The FDA has received reports of patients accidentally taking too much or too little of a compounded GLP-1 drug. Some compounded products may be dispensed in multi-dose vials that require patients to measure doses manually, increasing the risk of mistakes compared with prefilled, single-use pens used for many FDA-approved products.

Dosing errors can lead to severe nausea, vomiting, dehydration, low blood sugar (hypoglycemia), or other complications.

Different ingredient forms

The agency warned that some compounders may use salt forms of semaglutide, such as semaglutide sodium or semaglutide acetate, which are different from the active ingredient used in FDA-approved drugs. The FDA has stated it is not aware of lawful bases for compounding using these salt forms when the approved active ingredient is available.

Different chemical forms may not have the same safety or effectiveness profile as the approved product.

Contamination and sterility risks

Because compounded drugs are not manufactured under the same oversight as FDA-approved products, there may be greater risks of contamination or sterility problems if proper standards are not followed. Injectable medications require strict sterile conditions to prevent infection.

Adverse events reported

The FDA has received adverse event reports linked to compounded GLP-1 products. Reported problems include severe gastrointestinal symptoms, dehydration requiring medical care, and symptoms that could suggest pancreatitis, such as persistent, severe abdominal pain.

The agency has not described these reports as a recall, and it has not said that all compounded products are unsafe. But it has made clear that risks exist, especially when dosing errors or ingredient substitutions occur.

Who may be at higher risk?

People with type 2 diabetes, especially those using insulin or other blood sugar–lowering medications, may be at higher risk of hypoglycemia if dosing is incorrect. Patients with a history of pancreatitis or severe gastrointestinal disease should be especially cautious and discuss any GLP-1 therapy with their healthcare provider.

Interruptions in diabetes treatment can also have consequences. The CDC notes that poorly controlled diabetes increases the risk of heart, kidney, nerve, and eye complications. That makes safe access and proper dosing especially important.

What symptoms should prompt medical care?

Seek medical attention promptly if you experience:

Persistent or severe vomiting.
Signs of dehydration (dizziness, fainting, very little urination).
Symptoms of low blood sugar, such as shakiness, confusion, sweating, or rapid heartbeat.
Severe abdominal pain that may radiate to the back (possible pancreatitis).

If symptoms are severe or life-threatening, call emergency services.

How to protect yourself if you are prescribed a compounded GLP-1 drug

If you are considering or currently using a compounded GLP-1 medication, experts recommend several practical steps:

Verify the pharmacy. Make sure it is licensed by your state board of pharmacy or registered with the FDA as an outsourcing facility.
Ask about the exact ingredient. Confirm that the active ingredient is the same as in the FDA-approved product—not a salt form or different compound.
Understand your dosing instructions. If using a multi-dose vial, ask your pharmacist to demonstrate how to measure the correct dose.
Be cautious about marketing claims. Avoid products advertised as identical to brand-name drugs without clear documentation.

Patients and healthcare professionals can report side effects or product quality problems to the FDA’s MedWatch program.

Insurance, cost, and what may change next

Insurance coverage has played a major role in demand for compounded GLP-1 products. Some health plans limit coverage for weight-loss indications, and out-of-pocket costs for brand-name products can be high.

If shortages ease or the FDA changes its enforcement policies, access to compounded versions may shift. Pharmacies that compound copies of drugs no longer in shortage could face greater regulatory scrutiny. Patients currently using compounded products should stay in touch with their prescribing clinician about supply changes and alternatives.

What this means for readers

GLP-1 medications can be effective tools for managing diabetes and, in some cases, obesity. But compounded versions are not FDA-approved and may differ in dosing, ingredients, and manufacturing controls.

The FDA’s recent warnings are not a blanket ban, but they are a reminder to proceed carefully. Verify your pharmacy, understand what you are receiving, watch for side effects, and report problems. As shortages and policies evolve, staying informed—and working closely with your healthcare team—remains the safest path forward.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.